Topic: Growth Stocks

C.R. Bard Inc. $82 – New York symbol BCR

C.R. BARD INC. $82 (New York symbol BCR; Conservative Growth Portfolio, Consumer sector; Shares outstanding: 99.2 million; Market cap: $8.1 billion; WSSF Rating; Above average) makes medical devices in four main areas: Vascular products such as stents and catheters (25% of 2007 sales); Urology products such as drainage and incontinence devices (30%); Oncology products that detect and treat various types of cancer (25%); and Surgical Tools and other products (20%).

In June, 2008, Bard paid $70.7 million for Specialized Health Products International Inc. This company makes needles for syringes that reduce the risk of accidental punctures. That helps prevent the spread of infectious diseases. The purchase strengthened Bard’s vascular product portfolio.

Thanks to this acquisition, plus higher selling prices, Bard’s revenue in the three months ended September 30, 2008 rose 13.2%, to $616.8 million from $544.8 million a year earlier. International markets account for about 30% of Bard’s sales. If you disregard favorable foreign exchange rates, sales rose 11%.

Earnings in the latest quarter rose 8.9%, to $111.2 million from $102.1 million. Bard spent $46.2 million on share repurchases in the third quarter. Consequently, per-share earnings grew 13.5%, to $1.09 from $0.96.

Besides acquisitions, Bard also fuels its growth with heavy research spending. It spent $35.1 million (5.7% of revenue) on research in the latest quarter, up 3.2% from $34.0 million (6.2% of revenue) a year earlier.

Bard holds cash of $535.6 million or $5.40 a share, so it can continue to increase research spending. Long-term debt of $149.8 million is just 25% of Bard’s annual cash flow of around $575 million.

The stock now trades at 18.5 times its forecast 2008 earnings of $4.43 a share. That’s reasonable in light of its strong reputation, high market share and diversified source of revenues. The $0.64 dividend yields 0.8%.

C.R. Bard is a buy.

Comments are closed.